Provectus Biopharmaceutica-APVCT

13F holders, Q3 2024 (September 30)
7holders
0new positions
0sold out
$0.10avg. 13F price*

At the end of Q3 2024, 7 institutions reported holding Provectus Biopharmaceutica-A (PVCT) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holders were Home Federal Bank of Tennessee ($10K), Lee Danner & Bass Inc. ($5K) and Atlas Wealth LLC ($3K).

Company
Provectus Biopharmaceutica-A
CUSIP
74373P108
Latest filing quarter
Q2 2026

History

Number of 13F holders

02468 Q1 2024: 6Q1 2024Q2 2024: 7Q2 2024Q3 2024: 7Q3 2024Q4 2024: 6Q4 2024Q1 2025: 7Q1 2025Q2 2025: 7Q2 2025Q3 2025: 7Q3 2025Q4 2025: 5Q4 2025Q1 2026: 6Q1 2026Q2 2026: 4Q2 2026

Total Exit/New Position Q2 2024 → Q3 2024

InstitutionsTotal Value
New Positions0$0
Exits0$0

All 13F filers, Q2 2024 → Q3 2024: 2,000 shares sold, net −2,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 7 holders

Home Federal Bank of Tennessee 0.00% No change 100,000 $10K
Lee Danner & Bass Inc. 0.00% No change 50,000 $5K
Atlas Wealth LLC 0.00% No change 26,620 $3K
Academy Capital Management 0.00% No change 20,000 $2K
LBMC Investment Advisors, LLC 0.00% Reduce -9.1% 20,000 $2K
Financial Symmetry Inc 0.00% No change 10,191 $998
Huntington National Bank 0.00% No change 1 $0

"% of holder's portfolio" is PVCT's weight in each manager's 13F, not the share of Provectus Biopharmaceutica-A the manager owns.